21 results about "Neuroregulator" patented technology

An example of a system may include a processor and a memory device comprising instructions, which when executed by the processor, cause the processor to: access a patient metric of a subject; use the patient metric as an input to a machine learning algorithm, the machine learning algorithm to search a plurality of neuromodulation parameter sets and to identify a candidate neuromodulation parameter set of the plurality of neuromodulation parameter sets, the candidate neuromodulation parameter set designed to produce a non-regular waveform that varies over a time domain and a space domain; and program a neuromodulator using the candidate neuromodulation parameter set to stimulate the subject.

An embodiment collects a first set of patient data and a first set of treatment data associated with a patient population treated with neuromodulation. The embodiment clusters the patient population into a plurality of cohorts. The embodiment generates a plurality of states using a second set of patient data associated with a cohort in the plurality of cohorts. The embodiment generates a plurality of actions using a second set of treatment data associated with the cohort. The embodiment determines, based on the plurality of actions, a plurality of probabilities associated with a transition from a first state to a second state in the plurality of states. The embodiment generates, based on the plurality of probabilities, a neuromodulator action policy for a patient in the cohort.

The invention relates to the technical field of medical devices, and particularly discloses a diaphragm pacemaker and neural regulator linked respiration assisting system which comprises a respiratory dysfunction degree detection module, a diaphragm pacemaker and neural regulator linked respiration assisting module, a diaphragm pacemaker and neural regulator linked respiration assisting module and a diaphragm pacemaker and neural regulator linked respiration assisting module, the limit improvement degree evaluation module evaluates the limit improvement degree of the current respiratory dysfunction degree of the patient by the diaphragm pacemaker and the limit improvement degree of the current respiratory dysfunction degree of the patient by the neural regulator; the auxiliary participation degree determination module determines the respiration auxiliary participation degree of the diaphragm pacemaker to the patient and the respiration auxiliary participation degree of the neural regulator to the patient; the respiration assistance control module is used for respectively setting control parameters of the diaphragm pacemaker and control parameters of the neural regulator based on the respiration assistance participation degree of the diaphragm pacemaker to the patient and the respiration assistance participation degree of the neural regulator to the patient; the method is used for precisely controlling the diaphragm pacemaker and the neural regulator in a linkage mode to assist a patient in improving respiratory dysfunction of the patient.

Methods and apparatuses for setting a therapeutic dose of a neuromodulator implanted into a patient. The therapeutic dose typically includes a therapeutic dose duration including a ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage. The methods and apparatuses may use a testing ramp to identify a peak modulation voltage that is patient-specific and provides a maximized therapeutic effect while remaining comfortably tolerable by the patient during the application of energy by the neuromodulator.

A method for rehabilitating a patient with neurological deficit or neuromuscular disease, the method including providing a medical walker with an operably connected leg brace, wherein a swing linkage connects the leg brace to the medical walker proximate to a knee of a compromised limb of the patient. The method further includes sensing movement and position in space of the compromised limb of the patient via one or more sensors attached to the leg brace and generating limb data. The method also includes analyzing the limb data, and signaling one or more neuromodulators to activate based at least in part upon analysis of the limb data, wherein the signaling is timed to assist gait motion of the compromised limb.

The invention discloses a composition for improving immunity and delaying senescence and a preparation method thereof. Belongs to the technical field of functional health. The composition comprises the following components in parts by mass: 5-50 parts of collagen, 10-80 parts of paeonia ostii tea, 1-20 parts of an antioxidant, 3-10 parts of an intestinal microecology regulator and 1-3 parts of an energy metabolism and nerve regulator. According to the invention, through multi-system cooperation and multi-target intervention, dual effects of immune enhancement and senescence delay are realized. Through scientific compounding and a special process, the product has the advantages of stable components, uniform activity and good solubility. Animal experiments and theoretical models show that immune organs can be effectively protected, accumulation of aging markers is reduced, and a solution is provided for development of comprehensive anti-aging health products.

The present disclosure is directed to kappa opioid receptor ligands and pharmaceutical compositions thereof and their utility as neurological modulators (e.g., anti-nociceptive agents, antidepressants, anxiolytics, antipruritics). Specifically, the disclosed kappa opioid ligands are G-protein biased kappa opioid agonists containing a core and three different arms as is shown in Formula (A) below.

Methods and systems for providing stimulation therapy are disclosed. Embodiments of the system include an implantable stimulator and an external controller configured to control the implantable stimulator. A clinician can prescribe a set amount of stimulation therapy to a patient. The external controller is programmed with the prescription. As the patient uses the external controller and the stimulator device the external controller tracks the amount of stimulation the patient uses. Once the patient has used all of the prescribed therapy the patient may return to the clinician for a follow-up appointment.

A device and method for marking a surface, such as skin, to show the location of anticipated diffusion for a neuromodulator, such as botox, before administration of the neuromodulator is provided. The device comprises flexible leaf members having distal end surfaces and a separate tip end which transfer corresponding marks to the surface. The visualized anticipated diffusion pattern that results allows for a safer and more predictable outcome when administering the neuromodulator.

The present disclosure is directed to a bio-feedback sensor in combination with AI and ML that can be implemented to optimize neuromodulation parameters for the management of a medical condition such a type II diabetes. The bio-feedback obtained by the sensors is optimized by the ML tools to predict and recommend the upregulation or downregulating the neuroregulators to modulate treatment. The algorithms could also learn to sense a life-threating pathological state, or bio-chemical imbalance, and in the case of diabetes a life-threating low blood sugar level the system overrides to stimulate the target fibers that control organs to regulate blood glucose levels.

Devices, agents, and associated methods for selective modulation of renal nerves by localized delivery of neural ablative substances are disclosed herein. One aspect of the present technology is directed to a method for delivering a neuromodulatory agent (e.g., capsaicin) via a catheter to a kidney of the patient. The neuromodulatory agent selectively neuromodulates afferent renal nerves in a patient compared efferent renal nerves of the patient. The method can also include removing the catheter from the patient after delivering the neuromodulatory agent to conclude the procedure.

The present disclosure is directed to kappa opioid receptor ligands and pharmaceutical compositions thereof and their utility as neurological modulators (e.g., anti-nociceptive agents, antidepressants, anxiolytics, antipruritics). Specifically, the disclosed kappa opioid ligands are G-protein biased kappa opioid agonists containing a core and three different arms as is shown in Formula (A) below.

The present disclosure is directed to the neuromodulation of two or more neuronal targets in treatment of a medical condition. The neuronal targets can be sympathetic nerves, parasympathetic nerves or a combination of sympathetic and parasympathetic nerves. The neuromodulation of the neuronal targets can comprise stimulation of the neuronal target, a conduction block of the neuronal targets or a combination of stimulation and conduction blocks of the neuronal targets. The neuromodulation is performed by one or more neuroregulators which can comprise electrical or non-electrical neuroregulators. The neuromodulation of each of the neuronal targets can include the same or different start / end times, the same or different durations, and / or the same or different neuromodulation patterns. The neuromodulation of the first neuronal target works in cooperation with the neuromodulation of the second neuronal target to treat a medical condition.

This invention provides the application of neuregulin protein in the manufacture of drugs for preventing, treating, or delaying human heart failure, and methods for using such drugs. [Solution] The method includes: first examining the patient before treatment, wherein the examination includes detecting plasma levels of NT-proBNP or BNP; and subsequently providing appropriate treatment based on the examination results. If the examination results are within the optimal therapeutic range, the patient is suitable for treatment of heart failure by administering an effective dose of Neureglin.

An example catheter includes an elongated member configured to be navigated through vasculature of a patient to a target treatment site in a vessel of the patient, a needle positioned at a distal portion of the elongated member, the needle configured to be within the elongated member when in a delivery configuration and radially extended to puncture a vessel wall of the vessel at the target treatment site when in a deployed configuration, and an expandable balloon including a needle guide configured to position a distal end of the needle at a predetermined distance from a central axis of the elongated member when the balloon is in an expanded configuration and the needle is in the deployed configuration.

Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or sympathetic nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.

The present invention discloses a strain of Weissella confusa and its application in producing neuromodulators. The strain is called Weissella confusa W1h, and the deposit number is CGMCC NO.25725. The strain was deposited at the General Microbiology Center of China National Committee for the Preservation and Administration of Microorganisms at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing on September 15, 2022. Weissella confusa W1h in the present invention can secrete neuromodulators such as tryptophan, dopamine, short-chain fatty acids, etc., which can be used for the development and utilization of antidepressant probiotic products, and the strain has good tolerance to the gastrointestinal environment, has high intestinal adhesion and antibacterial activity, and can be used to improve the structure of intestinal microbial flora and inhibit the growth and reproduction of pathogenic bacteria.

The present disclosure relates to kappa opioid receptor ligands and pharmaceutical compositions thereof, and their utility as neurological modulators (e.g., antinociceptive agents, antidepressants, anxiolytic agents, antipruritic agents). Specifically, the disclosed kappa opioid ligands are G protein-biased kappa opioid agonists containing a core and three distinct arms, as shown in formula (A) below. TIFF2026507218000102.tif2335

Methods and systems for providing stimulation therapy are disclosed. Embodiments of the system include an implantable stimulator and an external controller configured to control the implantable stimulator. A clinician can prescribe a set amount of stimulation therapy to a patient. The external controller is programmed with the prescription. As the patient uses the external controller and the stimulator device the external controller tracks the amount of stimulation the patient uses. Once the patient has used all of the prescribed therapy the patient may return to the clinician for a follow-up appointment.

Medicaments and methods for preventing, treating, or delaying heart failure with preserved ejection fraction in mammals are provided. The present invention provides the use of neuregulin in the manufacture of a medicament for preventing, treating, or delaying heart failure with preserved ejection fraction in a mammal, and a pharmaceutical preparation for preventing, treating, or delaying heart failure with preserved ejection fraction in a mammal, the pharmaceutical preparation comprising an effective amount of neuregulin.

This invention belongs to the field of deuterated labeled compound synthesis technology, and discloses a method for deuterating indole compounds and its application. The deuteration method of this invention includes the following steps: mixing an indole compound, a transition metal catalyst, a complex ligand, an additive, and a deuteration solvent, reacting to obtain a deuterated product; the complex ligand includes a first ligand and a second ligand; the first ligand includes a lactam compound; the second ligand includes a pyridone compound; and the deuteration solvent includes deuterated acetic acid. The deuteration method of this invention achieves highly selective hydrogen-deuterium exchange at multiple sites on the indole ring of indole compounds (especially the difficult-to-modify C4-C7 sites) through the synergistic effect of the catalyst, the dual ligand, and the deuteration solvent system. Furthermore, it can be applied to the deuteration synthesis of drugs such as the anti-inflammatory drug indomethacin, the cancer adjuvant therapy drug tropisetron, and the neuromodulator melatonin, providing key technical support for the development of deuterated drugs.